Cargando…
Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319
Fibroblast growth factor 21 is a novel hormonal regulator with the potential to treat a broad variety of metabolic abnormalities, such as type 2 diabetes, obesity, hepatic steatosis, and cardiovascular disease. Human recombinant wild type FGF21 (FGF21) has been shown to ameliorate metabolic disorder...
Autores principales: | Kharitonenkov, Alexei, Beals, John M., Micanovic, Radmila, Strifler, Beth A., Rathnachalam, Radhakrishnan, Wroblewski, Victor J., Li, Shun, Koester, Anja, Ford, Amy M., Coskun, Tamer, Dunbar, James D., Cheng, Christine C., Frye, Christopher C., Bumol, Thomas F., Moller, David E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594191/ https://www.ncbi.nlm.nih.gov/pubmed/23536797 http://dx.doi.org/10.1371/journal.pone.0058575 |
Ejemplares similares
-
LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys
por: Adams, Andrew C., et al.
Publicado: (2013) -
Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo
por: Adams, Andrew C., et al.
Publicado: (2012) -
LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice
por: Le, Cong Thuc, et al.
Publicado: (2018) -
FGF21 Requires βklotho to Act In Vivo
por: Adams, Andrew C., et al.
Publicado: (2012) -
Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
por: Peng, Sheng-Bin, et al.
Publicado: (2017)